Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy. - Wikidata - awgldk - TriplyDB

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

http://www.wikidata.org/entity/Q36807370

about

Modelling hepatitis C therapy--predicting effects of treatment Clinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis C Real-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy.Reply to Harrington et al.Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or Serum SASLT guidelines: Update in treatment of Hepatitis C virus infection.HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapies Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis.Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test.Shortening the duration of therapy for chronic hepatitis C infection.Significance of HCV RNA monitoring in the era of new potent therapies.Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response Resurrection of response-guided therapy for sofosbuvir combination therapies.On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.Breaking Down Barriers to Care in Hepatitis C Virus Infection.Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile.Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers.Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C

P2860

Q26864673-F7413E59-176D-4745-AC45-5FCD0DA734EA Q28080225-7A78C531-FC45-420A-8C16-71A5585C8C44 Q35746376-E99161BB-3011-4E93-8C81-E040E0770986 Q35974458-4EC229B8-0063-4EE6-8FE5-0EE8B9714B94 Q36734896-F93C3E32-27FC-470F-8CC9-7FEAF93808BC Q37216507-C87C5C8B-5B0C-4B78-BAAD-33D02B3C008F Q37368417-0914A0F7-81B1-4A6E-874A-C24419247035 Q37671974-4EB0D29A-0D8F-4880-ABF1-47BB086F512B Q37692611-A928B363-9851-4131-821C-2A553A2539FE Q38376757-BE6B9C10-AF9D-41DC-8D90-02C55CB9A220 Q38627508-A08819F0-28B5-42F6-87BE-D71E30A5484B Q38899447-420E52E9-F640-4DBC-9B19-3731976ABA88 Q39194161-E8184415-91DB-4942-ADDD-9716FCB90EBE Q40171277-8B69EE3A-C064-4F0B-88C4-C7931EB11B64 Q40348977-A3AF1244-17EF-47E1-AD2B-D17977A02DA0 Q40529775-0202776C-7B6F-44C0-A1D4-EF2C8468E6A9 Q40652760-D6E23C0B-C02B-488A-9BC2-AEB1D56217C1 Q40671013-117E92D0-188B-4240-8FCB-5C6B4091FD39 Q42645615-71EFC453-F208-493E-9455-96FFBB79C7BE Q42979154-12C700E5-6090-46EC-AAFB-432116791D90 Q46388033-88447E6F-D40E-482A-90CE-0EBF1806784D Q46707427-40827675-4588-44C9-86A9-25F983A7AF16 Q47561388-57C2FCB0-61A6-465F-8AFD-7EEAA1C67A4A Q52326653-75192310-2EC2-4C16-8D3D-F02D1FCDCA6A Q58579652-5EE35C7E-9BF8-4AB9-8B50-38D3BA4800E3

P2860

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

http://www.wikidata.org/entity/Q36807370

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

@ast

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

@en

type

label

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

@ast

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

@en

prefLabel

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

@ast

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

@en

P1433

Q36807370-417787B9-F3BF-44F9-9E96-5673A3679169

P1476

Q36807370-1DFE2931-E947-45E1-B474-B8C4A88C289D

P2093

Q36807370-2436189A-238C-40B3-97EA-0F93D8CD8FA6

Q36807370-2567CBA1-2E22-4583-B952-39C1EDE8BC3A

Q36807370-4A587CFB-9AD7-4498-ACDF-5B312D4D16BE

Q36807370-58178781-0779-4DBD-8F1E-BD1EB28D58DE

Q36807370-EB9B5AD9-DE8A-49B5-9B44-5468674E4FC8

Q36807370-F65709CC-471D-4673-9207-00AD605F0782

P2860

Q36807370-04523F4E-1907-4ACB-8B84-0FC01693A6CC

Q36807370-05F217EC-69B7-443E-8F4D-EAC3CED264D8

Q36807370-08194867-DEEA-4677-A7C4-D8400114EB90

Q36807370-100763A2-B9CD-4A3D-8ADE-ECFF313A6273

Q36807370-252010CA-59A3-47E6-AEEA-AD4F7660678D

Q36807370-36B1472E-7638-4487-9AD0-122F7C47FE60

Q36807370-4BB66665-B164-48E3-987F-9088982D9F64

Q36807370-52BCC23D-59A7-41DF-86F4-F92CDB588D84

Q36807370-57EEBC09-8D37-4768-A80A-E51B6B5E01D2

Q36807370-5A78C754-EC24-4FDF-81CB-2247CEC4D977

P304

Q36807370-FA7DEAF3-F40B-4422-83A4-D615C355A064

P31

Q36807370-46928EFA-5B28-411C-899C-55B308F2A712

P356

Q36807370-461A9A69-11B9-49E8-9C2D-742757A4336F

P407

Q36807370-A29C93C9-570F-4EB0-9863-9F95984CF524

P433

Q36807370-6E2C46F1-2A3A-4E52-BABF-E37293F1DE39

P478

Q36807370-A551844D-C20E-4DCB-B60A-77D113EF7DDA

P50

Q36807370-AD3130A5-89EB-43FB-BB96-29507D9F07D2

P577

Q36807370-D96ADEEC-0194-4A7E-88D8-1E936F7988AB

P5875

Q36807370-FA213D76-7C95-4C15-A5FA-9F7137178809

P698

Q36807370-CB2FCCC5-98E4-427A-BAFB-EBD1A7FFFF9F

P921

Q36807370-DC068E0D-73B6-4E52-A0AB-99080F68E756

P932

Q36807370-9EB65F79-4F08-4836-9D0A-199801A40EFC

P356

P1433

Clinical Infectious Diseases

P1476

Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.

@en

P2093

Amy Nelson

http://www.w3.org/2001/XMLSchema#string

Anita Kohli

http://www.w3.org/2001/XMLSchema#string

Anu Osinusi

http://www.w3.org/2001/XMLSchema#string

Henry Masur

http://www.w3.org/2001/XMLSchema#string

Sreetha Sidharthan

http://www.w3.org/2001/XMLSchema#string

Zayani Sims

http://www.w3.org/2001/XMLSchema#string

P2860

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Boceprevir for untreated chronic HCV genotype 1 infection

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome.

Inteleukin-23 promotes interferon-α responsiveness in hepatitis C virus/HIV-coinfected patients

Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial.

Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits

P304

1743-1751

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIV170

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273156401

http://www.w3.org/2001/XMLSchema#string

P698

25733369

http://www.w3.org/2001/XMLSchema#string

P921

P932

4834854

http://www.w3.org/2001/XMLSchema#string